AdvisorShares Investments LLC trimmed its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) by 18.6% in the fourth quarter, HoldingsChannel reports. The firm owned 13,362 shares of the biopharmaceutical company’s stock after selling 3,053 shares during the quarter. AdvisorShares Investments LLC’s holdings in Sage Therapeutics were worth $290,000 as of its most […]
AdvisorShares Investments LLC lessened its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) by 18.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,362 shares of the biopharmaceutical company’s stock after selling 3,053 shares during the period. AdvisorShares Investments LLC’s holdings in […]
Sage Therapeutics (NASDAQ:SAGE – Get Free Report) and PepGen (NASDAQ:PEPG – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability. Profitability This table compares Sage Therapeutics and PepGen’s […]
Robert W. Baird assumed coverage on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a report issued on Wednesday morning, MarketBeat reports. The firm issued a neutral rating and a $15.00 price target on the biopharmaceutical company’s stock. Several other brokerages have also recently commented on SAGE. Truist Financial reduced their target price on […]
Citigroup initiated coverage on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a research note issued to investors on Wednesday, Marketbeat reports. The brokerage issued a sell rating and a $8.00 price target on the biopharmaceutical company’s stock. SAGE has been the subject of several other reports. The Goldman Sachs Group decreased their price […]